Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on May 8, 2012. The report announces the financial and operating results for the quarter ended March 31, 2012. The company is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the quarterly results have been issued via a press release.
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information in this Current Report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Review Exhibit 99.1 (the press release dated May 8, 2012) to obtain actual financial figures for the quarter ended March 31, 2012.
- Confirm the company's current status and any subsequent name changes, as the filing date is from 2012.